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ABSTRACT
This study reviewed 1787 episodes of peritoneal
dialysis (PD)-related peritonitis in 544 patients
between 1994 and 2003. The overall rate of
peritonitis was 0.68 episodes ⁄ year of PD, but
decreased from 1.10 to 0.46 episodes ⁄ year
between 1994 and 2003. The incidence of perito-
nitis caused by coagulase-negative staphylococci
declined between 1994 and 1998 from 0.21 to 0.06
episodes ⁄year of PD, coinciding with a reduction
in the use of spike PD sets. There was a 60.1%
response rate to antibiotics throughout the period,
but the percentage of cases that required modiﬁ-
cation of the initial empirical antibiotic regimen
rose from 13.6% to 58.7%, indicating that treat-
ment should be individualised.
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Peritonitis is the most important cause of treat-
ment failure in peritoneal dialysis (PD) patients
[1]. Peritonitis was common following the initial
development of PD, but the incidence has
decreased markedly during the past 15 years,
probably as a result of improvements in connec-
tion technology [2,3]. Peritonitis rates nowadays
are less than one episode ⁄ 20 patient-months in
most series [4,5]. The present study describes the
change in distribution of causative organisms in
PD-related peritonitis during a 10-year period in a
single centre in Hong Kong.
All episodes of PD-related peritonitis between
1994 and 2003 in the renal unit of the Prince of
Wales Hospital, Hong Kong, were reviewed. In
total, 1787 episodes of peritonitis in 544 patients
were identiﬁed. Data completeness was assured
by the computerised Renal Registry. A diagnosis
of peritonitis was based on at least two of the
following criteria [6]: (1) abdominal pain or
cloudy peritoneal dialysis efﬂuent (PDE); (2)
leukocytosis in PDE (white blood cells
> 100 ⁄mL); and (3) positive Gram-stain or culture
from PDE. Episodes with peritoneal eosinophilia
but with a negative bacterial culture were exclu-
ded. Bacterial culture of PDE was performed
Corresponding author and reprint requests: C. C. Szeto,
Department of Medicine & Therapeutics, Prince of Wales
Hospital, The Chinese University of Hong Kong, Shatin, Hong
Kong, China
E-mail: ccszeto@cuhk.edu.hk
Research Note 837
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 834–855
throughout the period in BacTAlert bottles (Org-
anon Teknika, Durham, NC, USA), according to
the recommendations of the International Society
of Peritoneal Dialysis (ISPD) [7]. Isolation and
identiﬁcation of bacteria, as well as determination
of antibiotic sensitivities, were performed accord-
ing to the ISPD guidelines [7].
The overall clinical management of these
patients has been described previously [8–12].
Empirical treatment of peritonitis, as summarised
in Table 1, generally followed the ISPD guide-
lines, which were amended over time. Antibiotic
regimens for individual patients were modiﬁed
when culture results were available. Appropriate
antibiotic therapy was continued for 14 days.
Treatment response was deﬁned as complete
resolution of peritonitis with antibiotics alone
(without relapse or catheter removal). Relapse
was deﬁned as recurrence of peritonitis caused by
the same organism within 30 days of completion
of antibiotic therapy [13]. All patients were
followed for at least 3 months following the
completion of treatment. Follow-up data were
assured by the Computer Management System of
the Hong Kong Hospital Authority.
The baseline demographic data of the 544
patients were similar to those of the overall PD
population reported previously [14]. The overall
rate of peritonitis was 0.68 episodes ⁄ year of PD.
The microbiological causes are summarised in
Table 2. A gradual reduction in the rate of perito-
nitis was observed during the 10-year period,
from 1.10 episodes ⁄ year of PD in 1994 to
0.46 episodes ⁄year of PD in 2003. The incidence
of both Gram-positive and culture-negative
peritonitis fell between 1994 and 1997, and then
remained low. There was also a gradual decline
in the incidence of Gram-negative peritonitis
between 1994 and 2003. When individual bacterial
species were considered, there was a substantial
decline in the incidence of peritonitis caused by
coagulase-negative staphylococci (CNS), and a
less marked decline in Staphylococcus aureus peri-
tonitis, while the incidence of peritonitis caused
by Streptococcus spp. remained static. The inci-
dence of peritonitis caused by CNS declined from
0.21 to 0.06 episodes ⁄ year of PD between 1994
and 1998, and then remained static. The incidence
of peritonitis caused by Pseudomonas spp. also
declined, from 0.11 to 0.04 episodes ⁄ year of PD
between 2000 and 2003. In contrast, the incidence
of peritonitis caused by Escherichia coli and
Klebsiella spp. remained static.
There was a progressive reduction in the use of
spike sets for PD between 1994 and 1998, which
paralleled the decline in Gram-positive perito-
nitis. The average rate of response to antibiotic
therapy was 60.1%, while 199 episodes (11.1%)
required catheter removal. A combination of
cefazolin and ceftazidime, the regimen recom-
mended by the current guidelines of the ISPD [7],
yielded a response rate of 66.9%. The rate of
response to antibiotic therapy remained static
during the 10-year period (details not shown);
however, the percentage of cases that required an
alteration in the antibiotic regimen rose from
13.6% in 1994 to 58.7% in 2003.
Table 1. Changes in the peritonitis management protocol
in the renal unit during the 10-year period of the study
Period Antibiotic regimen
January–December 1994a Imipenem–cilastatin ± vancomycin
January–December 1995 Ceftazidime + vancomycin
January–June 1996a Cefepime ± vancomycin
July 1996 to July 1998 Cefepime ± vancomycin; or
ceftazidime + vancomycin
August 1998 to October 1998 Sulperazone
November 1998 to March 1999 Cefepime ± vancomycin
April 1999 to February 2001 Netilmicin + cefazolin
March 2001 to February 2002a Ceftazidime + cefazolin; or
imipenem–cilastatin
March 2002 to date Ceftazidime + cefazolin
Dosages of all antibiotics generally followed those described by the International
Society of Peritoneal Dialysis Ad Hoc Committee [7].
aProspective studies underway [10–12].
Table 2. Microbiological causes of peritonitis episodes
during a 10-year period
Organisms identiﬁed No. of episodes (%)
Gram-positive organisms 722 (40.4)
Staphylococcus aureus 212 (11.9)
MSSA 174 (9.7)
MRSA 38 (2.1)
CNS 217 (12.1)
Enterococcus spp. 24 (1.3)
Other Streptococcus spp. 155 (8.7)
Corynebacterium spp. 20 (1.1)
Other diphtheroides 34 (1.9)
Others 60 (3.4)
Gram-negative organisms 520 (29.1)
Pseudomonas spp. 227 (12.7)
Stenotrophomonas spp. 13 (0.7)
Escherichia coli 109 (6.1)
Klebsiella spp. 47 (2.6)
Acinetobacter spp. 45 (2.5)
Others 79 (4.4)
Fungi 45 (2.5)
Candida spp. 41 (2.3)
Filamentous fungi 4 (0.2)
Mycobacteria 17 (1.0)
Mycobacterium tuberculosis 11 (0.6)
Atypical mycobacteria 6 (0.3)
Polymicrobial growth 192 (10.7)
Culture-negative 291 (16.3)
Total 1787
MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus; CNS,
coagulase-negative staphylococci.
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The present study found that the overall inci-
dence of PD-related peritonitis decreased by more
than half during the 10-year study period. When
speciﬁc organisms were examined, the incidence
of peritonitis caused by CNS decreased by about
75%, while the incidence of that caused by
S. aureus was halved. This declining incidence of
Gram-positive peritonitis was not an unexpected
ﬁnding. It is agreed generally that the incidence of
peritonitis decreased markedly as a result of
improvements in connection technology [2,3].
Almost all patients in the present series have
used a disconnect system since 1998, and the
incidence of Gram-positive peritonitis remained
at a low but static level between 1998 and 2002,
further supporting the role of the disconnect
system. Interestingly, the incidence of Gram-
positive peritonitis showed a further signiﬁcant
decrease in 2003. The precise reason for this
further decrease remains unknown, but it may
have resulted from the outbreak of severe acute
respiratory syndrome (SARS) in Hong Kong,
which reinforced the personal hygiene and asep-
tic precautions taken with these patients. Atten-
tion to such precautions has been proved to
reduce the rate of infection in PD patients [15].
The increasing percentage of cases which
required an alteration in the antibiotic regimen
suggested that antibiotic resistance is becoming
increasingly common. An increasing prevalence
of infections in PD patients caused by methicillin-
resistant CNS was noted by Holley et al. [16] in
the 1980s, and, more recently, by Kim et al. [17].
Unfortunately, no data regarding the patterns of
antibiotic resistance were available in the current
retrospective analysis.
In summary, a gradual decline was observed in
the incidence of PD-related peritonitis during the
past 10 years, and appeared to be related partly to
an increase in the utilisation of disconnect PD
systems. There was, however, an increased need
to modify the initial empirical antibiotic regimen
during this period, indicating that treatment
should be tailored individually.
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